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Abstract
Background: The availability of suitable recombinant protein is still a major bottleneck in protein
structure analysis. The Protein Structure Factory, part of the international structural genomics
initiative, targets human proteins for structure determination. It has implemented high throughput
procedures for all steps from cloning to structure calculation. This article describes the selection
of human target proteins for structure analysis, our high throughput cloning strategy, and the
expression of human proteins in Escherichia coli host cells.
Results and Conclusion: Protein expression and sequence data of 1414 E. coli expression clones
representing 537 different proteins are presented. 139 human proteins (18%) could be expressed
and purified in soluble form and with the expected size. All E. coli expression clones are publicly
available to facilitate further functional characterisation of this set of human proteins.
Background
The Protein Structure Factory
The Protein Structure Factory (PSF) is a joint endeavour of
universities, research institutes and companies from the
Berlin area [1,2]. It takes part in the international struc-
tural genomics initiative [3,4] and aims at the determina-
tion of human protein structures by X-ray diffraction
methods and NMR spectroscopy using standardised high-
throughput procedures. A complete pipeline has been
established for this purpose that comprises cloning, pro-
tein expression in small and large scale, biophysical pro-
tein characterisation, crystallisation, X-ray diffraction and
structure calculation.
It is known that eukaryotic proteins are often difficult to
express in Escherichia coli [5]. Only a certain fraction of
these proteins can be overproduced in E. coli in sufficient
yield without formation of inclusion body aggregates or
proteolytic degradation. Alternative expression systems
include cell cultures of various eukaryotic organisms and
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been greatly improved since 1999, when the PSF project
was initiated. In the meantime, E. coli [5-7] and wheat
germ [8]in vitro protein synthesis is routinely used by
structural genomics projects. At the PSF, yeast expression
hosts, Saccharomyces cerevisiae and Pichia pastoris, were suc-
cessfully established as alternative systems to E. coli, as
described in detail previously [9-11]. We will focus here
on the results obtained with the E. coli expression system.
E. coli strains and vectors
The T7 RNA polymerase-dependent E. coli expression vec-
tor system (pET-vectors) is a universal system to generate
recombinant protein for structural analysis [12]. pET vec-
tors are usually combined with the E. coli B strain BL21
and derivatives that are engineered to carry the T7 RNA
polymerase gene. These strains, however, have limitations
in cloning and stable propagation of the expression con-
structs. Expression vectors which are regulated by the lac
operator are independent of the host strain. Recombina-
tion-deficient E. coli K-12 strains are suitable for cloning
because of their high transformation rates and because
they allow for stable propagation of recombinant con-
structs. The strain SCS1 (Stratagene; hsdR17(rK- mK+) recA1
endA1 gyrA96 thi-1 relA1 supE44) was found to perform
well at the PSF in cloning experiments. It grows relatively
fast and allows for robust protein expression.
Affinity tags allow for standardised protein purification
procedures. The first vector that was used routinely in the
PSF, pQStrep2 (GenBank AY028642, Figure 1), is based
on pQE-30 (Qiagen) and adds an N-terminal His-tag [13]
for metal chelate affinity chromatography (IMAC) and a
C-terminal Strep-tag II [14,15] to the expression product.
pQStrep2 allows for an efficient two-step affinity purifica-
tion of the encoded protein, as demonstrated in a study of
an SH3 domain [16]. The eluate of the initial IMAC is
directly loaded onto a Streptactin column. Thereby, only
full-length expression products are purified and degrada-
tion products are removed. However, the two tags, which
are flexible unfolded peptides, remain on the protein and
may interfere with protein crystallisation, although we
could show that crystal growth may be possible in their
presence even for small proteins [16]. To exclude any neg-
ative influence by the affinity tags, another vector, pQTEV
(GenBank AY243506, Figure 1), was constructed. pQTEV
allows for expression of N-terminal His-tag fusion pro-
teins that contain a recognition site of the tobacco etch
virus (TEV) protease for proteolytic removal of the tag.
Codon usage has a major influence on protein expression
levels in E. coli [17], and eukaryotic sequences often con-
tain codons that are rare in E. coli. Especially the arginine
codons AGA and AGG lead to low protein yield [18]. This
can be alleviated by introducing genes for overexpression
Vector mapsFigure 1
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have used the plasmid pSE111 (Figure 1) carrying the
argU gene for this purpose. pSE111 is compatible with
pQTEV and other common expression vectors. It carries
the lacIQ gene for overexpression of the Lac repressor,
which is required when using promoters regulated by lac
operators. pSE111 was used at the PSF in combination
with the expression vectors pQStrep2 and pGEX-6P-1.
Strains for overexpression of rare tRNAs are available from
Invitrogen (BL21 Codon Plus) and Novagen (Rosetta).
The Rosetta strain contains the chloramphenicol-resistant
pRARE plasmid that supplies tRNAs for the codons AUA,
AGG, AGA, CUA, CCC, GGA [19]. This plasmid is used at
the PSF in combination with pQTEV and pGEX-6P-2.
The Additional file 1 psfClones.xml lists the vector and
helper plasmid for overexpression of rare tRNAs that was
used for each individual clone.
Selection of target proteins
We selected target proteins with higher-than-average
chances of successful expression in E. coli and crystallisa-
tion [1]. Proteins were excluded for which sequence anal-
ysis predicted that structure determination would be
difficult. Starting from the complete set of known human
proteins, potentially difficult target proteins and proteins
of known structure were excluded according to the follow-
ing criteria:
• Membrane proteins are known to be complicated targets
for structure determination and were excluded. Mem-
brane proteins were identified with the program TMHMM
[20,21].
• Since very large proteins are often difficult to express, the
maximal length of target proteins was set to 500 amino
acids.
• Protein regions that are unstructured or only partially
structured [22] may lead to difficulties during protein
expression and purification. Unstructured regions are sus-
ceptible to proteolyic attack, and represent an obstacle to
protein crystallisation. A large proportion of intrinsically
unstructured protein sequences are characterised by
sequence stretches of low complexity and tandem repeats
[23]. Proteins with low complexity regions of more than
20 amino acids length, detected by the SEG program, or
with more than one region were excluded [24,25].
• Coiled-coil proteins were excluded from our target list,
since this fold is not novel, and structural analysis of
coiled coils requires special attention. Many coiled coil
proteins form hetero-complexes with other coiled-coil
proteins and cannot be studied without their binding
partner. Coiled-coils domains are long, extended
structures which can usually only be crystallised as
domains, i.e. expression constructs lacking other domains
have to be prepared. To identify coiled-coil proteins, the
program COILS was used [26-28].
• The cellular localisation of target proteins was assigned
with the Meta_A(nnotator) [29,30]. Target proteins anno-
tated to be localised in the extracellular space, endoplas-
mic reticulum, Golgi stack, peroxisome or mitochondria
were excluded from expression in E. coli. Many of these
proteins require formation of disulphide bonds for correct
folding, but these are generally not formed in the reducing
environment of the E. coli cytoplasm. Therefore, these
proteins were allocated only for extracellular expression
by yeast host cells. Proteins with predicted intracellular
localisation or which were not assigned with a localisa-
tion by Meta_A(nnotator) were expressed in the cytosol of
E. coli.
• Potential target proteins were matched to the sequences
of proteins with known structure at the Protein Data Bank
(PDB) [31]. PSI-BLAST [32] was used to detect even very
distinct homologies to PDB entries to rule out proteins
with known folds. This filter was later replaced by a less
stringent one, which considers the sequence identity and
'coverage' of matches to PDB sequences. The coverage is
the length of the sequence match divided by the protein
length. According to the less stringent filter, proteins with
60% or more sequence identity over 90% or more of the
sequence length were excluded. Thereby target proteins
could be included of which only a part, e.g. a single
domain, has a known structure.
Results
Target lists
The first target list was generated in 1999, when the PSF
project started, from the set of all human proteins known
at that time. This set was filtered as described above. PSI-
BLAST was used to match potential target proteins to the
PDB and to include only proteins of presumably novel
folds. To enable high-throughput cloning, we selected tar-
get proteins for which full-length cDNA clones were avail-
able. In 1999, cDNA clones of the IMAGE consortium
represented the main public source of sequenced cDNA
clones [33]. However, only partial sequence information
existed for these clones – the EST sequences of the dbEST
database [34] – and only a small proportion contained
complete open reading frames (full-ORF clones). 490 pro-
teins were selected which met the selection criteria, had
no match to PDB detected by PSI-BLAST and for which
full-ORF IMAGE cDNA clones were available.
In 2003, a second target list was compiled from novel full-
length cDNAs discovered by the German cDNA consor-
tium [35,36]. The same filter criteria as for the first targetPage 3 of 13
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taken into account. Proteins with a PDB match of 60% or
more sequence identity and 90% sequence coverage were
excluded, resulting in a target list of 259 proteins.
A third set of target proteins was selected from a human
cDNA expression library (hEx1), which was cloned in a
bacterial expression vector. This library was screened for
expression clones on high density arrays and by high-
throughput protein expression and purification experi-
ments [37-40]. This identified 2,700 clones expressing
soluble His-tag fusion proteins that could be purified by
affinity chromatography [39]. The cDNA inserts of these
clones were sequenced and assigned to sequences of the
Ensembl database [41]. 141 proteins represented by
clones of the expression library where selected as targets
for structural analysis [39]. These clones express soluble,
full-length proteins, of which the three-dimensional struc-
ture was unknown.
The numbers of targets and success rates grouped by the
type of target cDNA clone are summarised in Table 1.
Generation and characterisation of expression clones
We established a common cloning strategy that allows for
easy shuttling of cDNA fragments between different E. coli
and yeast vectors. We adopted a cloning system that adds
only a minimal number of extra amino acids to the pro-
tein of interest and therefore decided to clone with restric-
tion enzymes instead of using alternative systems, such as
Invitrogen's Gateway system or ligation independent
cloning [42].
The PSF has been working with more than a thousand tar-
get proteins to date. Suitable cDNA clones were selected
and subcloned into the E. coli expression vectors pQTEV
GenBank AY243506 and pQStrep2 AY028642[16]. These
vectors provide for an N-terminal His-tag; pQStrep2 also
encodes an C-terminal Strep-tag-II. Some proteins have
also been expressed as GST fusion proteins using the vec-
tors pGEX-4T2 or pGEX-6P1 (Amersham Biosciences).
Expression of protein coding genes from multiple trans-
formants per target was tested under multiple conditions.
Standardisation and automation was introduced to
achieve this throughput. Expression clones were charac-
terised by small scale protein synthesis at different tem-
peratures, 37°C, 30°C and 25°C, in 1 ml volumes in
deep-96-well microplates. Proteins were purified in paral-
lel by a pipetting robot, as described previously [43]. 10%
of the purified protein eluate from a 1 ml culture was ana-
lysed by SDS-PAGE. For each protein expression experi-
ment, the size of the expression product was recorded and
the amount of protein was classified into four categories:
none, weak, moderate and strong expression. This classifi-
cation is arbitrary to a certain degree, however, we found
it sufficient to select suitable clones for protein produc-
tion scale-up.
1414 clones for 537 target proteins were successfully
cloned in E. coli expression vectors, with 473, 191 and 94
target proteins corresponding to target lists one (IMAGE
clones), two (DKFZ clones) and three (hEx1 clones),
respectively. Clones for 139 different target proteins were
found to be expressed in soluble form by E. coli. Figure 2
and Table 2 show the result of small scale expression and
purification of these proteins. The yield varied signifi-
cantly among different target proteins. The Additional file
1 psfClones.xml contains further details on the expression
clones, such as vector, strain and helper plasmid for over-
expression of rare tRNAs.
Biophysical properties of proteins which could be
expressed in soluble form in E. coli were compared against
all tested proteins. We found no significant correlation
between expression success and either protein length or
mean net charge (data not shown). However, when ana-
lysing the mean hydrophobicity, we found that hydro-
phobic proteins are less likely to be expressed in soluble
form. Only one of 139 well expressed proteins has a mean
hydrophobicity of more than 0.2, while 8% of the other
proteins are above this value. This group of proteins does
not contain transmembrane helices according to
Table 1: Origin of template cDNA clones Numbers of targets grouped by type of template cDNA clone
Target list Number of targets Number of successfully 
cloned cDNA
Number of proteins with 
soluble expression
Number of structures
1 – IMAGE clones 490 264 54 3
2 – cDNA consortium 259 185 34 2
3 – hEx1 library 141 88 51 3
all 890 537 139 8Page 4 of 13
(page number not for citation purposes)
Microbial Cell Factories 2005, 4:21 http://www.microbialcellfactories.com/content/4/1/21SDS-PAGE of purified human proteinsFigure 2
SDS-PAGE of purified human proteins. 15% SDS-PAGE (Coomassie-stained) of proteins expressed in small scale in E. coli 
and purified by automated immobilised metal chelate affinity chromatography as described in [43]. The identities of the purified 
proteins are indicated in Table 2. Protein expression was induced at the temperature that is optimal for the individual clone. 
These temperatures are listed in the supplementary file psfClones.xml. M: Molecular weight marker.
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Microbial Cell Factories 2005, 4:21 http://www.microbialcellfactories.com/content/4/1/21Table 2: PSF E. coli expression clones with soluble expression products. The table corresponds to the proteins shown in Figure 2. More 
detailed information is available in the supplementary XML file, Additional file 1.
NCBI 
Entrez 
gene ID
Gene symbol, name Protein 
accession
RZPD clone ID Sequence 
verified, non-
silent mutations
Clone 
accession
Protein 
size [Da]
Protein 
gel, lane
39 ACAT2, acetyl-Coenzyme A acetyltransferase 
2
AAM00223 PSFEp250C082 partly, none 44,177 D, 24
203 AK1, adenylate kinase 1 BAA78534 PSFEp250B112 yes, none DQ000549 24,558 C, 21
689 BTF3, basic transcription factor 3 CAA37376 PSFEp758D0224 no 20,622 A, 27
830 CAPZA2, capping protein (actin filament) 
muscle Z-line, alpha 2
AAC60382 PSFEp758H1226 no 59,649 A, 4
1036 CDO1, cysteine dioxygenase, type I BAA12872 PSFEp758D0124 yes, none DQ000531 25,895 E, 16
1428 CRYM, crystallin, mu AAC16914 PSFEp758B0810 yes, none DQ000499 36,275 D, 4
1460 CSNK2B, casein kinase 2, beta polypeptide CAA34379 PSFEp758H0422 no 26,209 B, 12
1606 DGKA, diacylglycerol kinase, alpha 80kDa AAC34806 PSFEp758F0324 yes, none DQ000529 16,408 A, 23
1627 DBN1, drebrin 1 AAH07567 PSFEp250C052 partly, none 74,354 C, 31
1635 DCTD, dCMP deaminase AAC37579 PSFEp250B121 yes, none DQ000535 22,938 E, 25
1937 EEF1G, eukaryotic translation elongation 
factor 1 gamma
AAH15813 PSFEp250H061 partly, none 53,045 C, 11
1974 EIF4A2, eukaryotic translation initiation factor 
4A, isoform 2
AAH48105 PSFEp250H052 partly, none 49,301 D, 20
2963 GTF2F2, general transcription factor IIF, 
polypeptide 2, 30 kDa
CAA42419 PSFEp250B012 yes, none DQ000547 31,304 C, 17
2992 GYG, glycogenin AAB00114 PSFEp758H1122 yes, none DQ000517 40,403 B, 4
3151 HMGN2, high-mobility group nucleosomal 
binding domain 2
AAA52678 PSFEp250E102 yes, none DQ000559 12,314 D, 27
3312 HSPA8, heat shock 70 kDa protein 8 BAB18615 PSFEp250E022 partly, none 56,444 D, 31
3735 KARS, lysyl-tRNA synthetase AAH04132 PSFEp250D032 partly, A116G 70,976 D, 16
3925 STMN1, stathmin 1/oncoprotein 18 CAC16020 PSFEp250F072 yes, none DQ000556 20,225 D, 19
4043 LRPAP1, low density lipoprotein receptor-
related protein associated protein 1
AAC67373 PSFEp250G031 yes, none DQ000540 44,391 C, 22
4695 NDUFA2, NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex, 2
AAD27762 PSFEp250D091 no 13,843 C, 13
4698 NDUFA5, NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex, 5
AAD21526 PSFEp250A0510 no 16,381 A, 13
5184 PEPD, peptidase D AAH28295 PSFEp250H122 yes, none DQ000560 D, 29
5202 PFDN2, prefoldin 2 AAF17218 PSFEp250D112 yes, none DQ000555 19,570 D, 17
5412 UBL3, ubiquitin-like 3 AAD02323 PSFEp758A0510 yes, none DQ000501 15,657
5502 PPP1R1A, protein phosphatase 1, regulatory 
(inhibitor) subunit 1A
AAB02402 PSFEp758G0124 yes, none DQ000526 21,862 A, 15
5716 PSMD10, proteasome (prosome, macropain) 
26S subunit, non-ATPase, 10 (gankyrin)
AAH11960 PSFEp250A062 yes, none DQ000544 27,351 C, 9
5717 PSMD11, proteasome (prosome, macropain) 
26S subunit, non-ATPase, 11
AAH04430 PSFEp250B122 yes, none DQ000548 50,390 C, 19
5877 RABIF, RAB interacting factor AAB18264 PSFEp250C021 no 16,761 E, 23
6133 RPL9, ribosomal protein L9 BAA03401 PSFEp758E0124 yes, none DQ000524 24,786 A, 28
6156 RPL30, ribosomal protein L30 CAA55820 PSFEp758A1113 yes, none DQ000503 15,284 D, 6
6191 RPS4X, ribosomal protein S4, X-linked BC007308 PSFEp758A0923 no 28,670
6342 SCP2, sterol carrier protein 2 AAA03559 PSFEp758C0723 yes, none DQ000515 16,668 B, 1
6451 SH3BGRL, SH3 domain binding glutamic acid-
rich protein like
AAC27445 PSFEp758C0713 no 15,274 D, 2
6728 SRP19, signal recognition particle 19 kDa CAA31280 PSFEp758E0317 no 41,156
6888 TALDO1, transaldolase 1 AAB53943 PSFEp758B0711 partly, none 40,040 D, 1
6990 TCTE1L, t-complex-associated-testis-
expressed 1-like
AAA57444 PSFEp758D0814 no 38,062 A, 3
6993 TCTEL1, t-complex-associated-testis-
expressed 1-like 1
BAA09317 PSFEp758F1123 yes, none DQ000521 13,719 A, 14
7001 PRDX2, peroxiredoxin 2 AAH03022 PSFEp250A042 yes, none DQ000546 24,815 C, 30
7178 TPT1, tumor protein, translationally-
controlled 1
CAA34200 PSFEp250G011 yes, none DQ000539 22,518 C, 14
7247 TSN, translin CAA55341 PSFEp250B111 yes, none DQ000538 29,106 C, 12
7353 UFD1L, ubiquitin fusion degradation 1-like N P_005650 PSFEp758G0123 yes, none DQ000519 41,777 D, 9
7390 UROS, uroporphyrinogen III synthase AAA60273 PSFEp758G0323 no 29,894 D, 11Page 6 of 13
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defective repair in Chinese hamster cells 4
AAH16314 PSFEp250A033 partly, none 41,211 D, 26
7531 YWHAE, tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation 
protein, epsilon
AAH01440 PSFEp250H041 yes, A146G DQ000541 32,097 C, 24
8125 ANP32A, acidic (leucine-rich) nuclear 
phosphoprotein 32 family, member A
AAB91548 PSFEp250D092 yes, none DQ000553 31,509 D, 22
8214 DGCR6, DiGeorge syndrome critical region 
gene 6
CAA65339 PSFEp758G0324 yes, none DQ000533 12,111 E, 19
8407 TAGLN2, transgelin 2 BAA04802 PSFEp250F062 yes, none DQ000550 25,314 C, 27
8544 PIR, pirin CAA69195 PSFEp758A0213 yes, none DQ000498 34,613 C, 1
8575 PRKRA, protein kinase, interferon-inducible 
double stranded RNA dependent activator
CAB66550 PSFEp250D014 yes, none DQ000578 37,328 E, 9
8677 STX10, syntaxin 10 AAC05087 PSFEp250D102 yes, none DQ000552 25,369 D, 18
8724 SNX3, sorting nexin 3 AAC16040 PSFEp758A0323 yes, none DQ000514 20,029 B, 15
8896 G10, maternal G10 transcript AAH22821 PSFEp250F011 yes, A394G DQ000536 19,766 C, 16
8926 SNURF, SNRPN upstream reading frame AAD31391 PSFEp250A0610 no 11,334 C, 25
9049 AIP, aryl hydrocarbon receptor interacting 
protein
AAB59004 PSFEp758F1024 yes, none DQ000528 40,589 A, 21
9158 FIBP, fibroblast growth factor (acidic) 
intracellular binding protein
CAG33030 PSFEp250B022 partly, T602C 44,803 C, 20
9168 TMSB10, thymosin, beta 10 AAB25225 PSFEp758A0124 yes, none DQ000522 6,292 A, 18
9337 CNOT8, CCR4-NOT transcription complex, 
subunit 8
AAH17366 PSFEp758E0524 yes, none DQ000523 36,354 A, 24
9453 GGPS1, geranylgeranyl diphosphate synthase 1 AAH05252 PSFEp250E052 partly, none 37,795 D, 23
9465 AKAP7, A kinase (PRKA) anchor protein 7 AAC39715 PSFEp758E0415 no 34,000 A, 1
9796 PHYHIP, phytanoyl-CoA hydroxylase 
interacting protein
BAA13402 PSFEp758C1124 yes, T806C DQ000530 40,497 A, 29
10000 AKT3, v-akt murine thymoma viral oncogene 
homolog 3
CAB55977 PSFEp250B063 yes, none 56,516 E, 20
10063 COX17, COX17 homolog, cytochrome c 
oxidase assembly protein (yeast)
AAA98114 PSFEp758D0723 yes, none DQ000516 8,182 B, 3
10094 ARPC3, actin related protein 2/3 complex, 
subunit 3
AAB64191 PSFEp758G0811 yes, none DQ000507 23,047 D, 7
10169 SERF2, small EDRK-rich factor 2 AAC63516 PSFEp250A057 no 9,821 C, 23
10228 STX6, syntaxin 6 AAH09944 PSFEp758G0526 yes, none DQ000509 32,100 B, 7
10247 HRSP12, heat-responsive protein 12 (14.5 kDa 
translational inhibitor protein, p14.5)
CAA64670 PSFEp758H0822 yes, none DQ000518 15,760 D, 12
10290 APEG1, aortic preferentially expressed 
protein 1
AAH06346 PSFEp250B082 yes, none DQ000543 15,614 E, 18
10539 TXNL2, thioredoxin-like 2 AAH05289 PSFEp250A022 partly, none 40,357 C, 26
10588 MTHFS, 5,10-methenyltetrahydrofolate 
synthetase
AAC41945 PSFEp758B0824 no 24,522 D, 15
10589 DRAP1, DR1-associated protein 1 (negative 
cofactor 2 alpha)
AAH10025 PSFEp250C042 yes, none DQ000542 25,273 E, 3
10598 AHSA1, AHA1, activator of heat shock 90 
kDa protein ATPase homolog 1 (yeast)
AAD09623 PSFEp250B091 no 41,199 C, 15
10606 PAICS, phosphoribosylaminoimidazole 
carboxylase
AAH19255 PSFEp758G0226 partly, none 50,005 A, 5
10842 C7orf16, chromosome 7 open reading frame 
16
AAF03537 PSFEp758F0923 no 19,132 B, 2
10856 RUVBL2, RuvB-like 2 (E. coli) AAH04531 PSFEp250C072 partly, none 54,083 D, 25
10912 GADD45G, growth arrest and DNA-damage-
inducible, gamma
AAC83329 PSFEp758F0111 yes, none DQ000504 19,621 C, 4
10933 MORF4L1, mortality factor 4 like 1 AAH22845 PSFEp250G051 partly, none 40,155 C, 10
10963 STIP1, stress-induced-phosphoprotein 1 AAA58682 PSFEp250A012 partly, A86C 65,566 C, 28
11140 CDC37, CDC37 cell division cycle 37 
homolog (S. cerevisiae)
AAH08793 PSFEp250E042 partly, none 47,394 D, 28
11316 COPE, coatomer protein complex, subunit 
epsilon
AAH07250 PSFEp758G1126 yes, none DQ000510 37,406 B, 9
11333 PDAP1, PDGFA associated protein 1 AAH07873 PSFEp250A073 yes, none DQ000554 23,553 D, 30
11337 GABARAP, GABA(A) receptor-associated 
protein
AAD02337 PSFEp758H0922 no 15,185 D, 10
Table 2: PSF E. coli expression clones with soluble expression products. The table corresponds to the proteins shown in Figure 2. More 
detailed information is available in the supplementary XML file, Additional file 1. (Continued)Page 7 of 13
(page number not for citation purposes)
Microbial Cell Factories 2005, 4:21 http://www.microbialcellfactories.com/content/4/1/2111344 PTK9L, PTK9L protein tyrosine kinase 9-like 
(A6-related protein)
N P_009215 PSFEp758A0127 yes, none DQ000525 42,473 E, 13
22818 COPZ1, coatomer protein complex, subunit 
zeta 1
AAD34115 PSFEp758A0812 yes, none DQ000497 22,698 D, 3
22919 MAPRE1, microtubule-associated protein, RP/
EB family, member 1
CAB53072 PSFEp250C112 yes, none DQ000557 32,923 D, 21
22931 RAB18, RAB18, member RAS oncogene family CAB66668 PSFEp250C118 no 25,900 B, 27
23589 CARHSP1, calcium regulated heat stable 
protein 1
AAD25021 PSFEp778D072 no 40,934
25842 ASF1A, ASF1 anti-silencing function 1 homolog 
A (S. cerevisiae)
AAD34093 PSFEp758E1224 yes, none DQ000532 25,891 E, 17
25843 PREI3, preimplantation protein 3 AAD34090 PSFEp758B0812 yes, none DQ000500 28,532 C, 2
25996 DKFZP566E144, small fragment nuclease AAD34109 PSFEp758G0423 yes, none DQ000520 25,021 D, 13
26289 AK5, adenylate kinase 5 AAH12467 PSFEp250G042 yes, 3 bp 
insertion at 3' 
end
DQ000558 24,897 E, 14
26353 HSPB8, heat shock 22 kDa protein 8 CAB66870 PSFEp250G125 yes, none DQ000565 24,527 B, 16
27095 TRAPPC3, trafficking protein particle complex 
3
AAB96936 PSFEp758A0513 yes, none DQ000502 22,774 C, 3
27249 C2orf25, chromosome 2 open reading frame 
25
AAD20048 PSFEp758D1124 no 35,864 A, 22
27335 eIF3k, eukaryotic translation initiation factor 3 
subunit 12
BAA76626 PSFEp758D0923 no 26,326 D, 8
27430 MAT2B, methionine adenosyltransferase II, 
beta
CAB66599 PSFEp250A114 yes, none DQ000575 40,476 B, 21
28970 PTD012, PTD012 CAB66540 PSFEp250B014 yes, none DQ000586 38,042 E, 24
29789 PTD004, GTP-binding protein PTD004 CAB66481 PSFEp250H073 yes, none DQ000564 47,609 B, 18
30819 KCNIP2, Kv channel interacting protein 2 CAB66656 PSFEp250G064 yes, none DQ000562 28,964 E, 5
51001 CGI-12, CGI-12 AAH12995 PSFEp250B092 yes, none DQ000545 40,832 C, 8
51076 CUTC, cutC copper transporter homolog (E. 
coli), CGI-32
AAH21105 PSFEp758E1112 yes, none DQ000505 31,811 C, 5
51078 THAP4, THAP domain containing 4 AAD27745 PSFEp250H116 no 21,550 C, 7
51155 HN1, hematological and neurological 
expressed 1
AAH01420 PSFEp758G0126 yes, 3 bp 
deletion at 5' 
end, G457A
DQ000508 18,937 C, 6
51160 VPS28, vacuolar protein sorting 28 (yeast) AAF00499 PSFEp758C0323 yes, none DQ000513 26,692 B, 14
51335 NEUGRIN, mesenchymal stem cell protein 
DSC92
CAD39160 PSFEp250B084 yes, none DQ000566 27,342 B, 28
51397 COMMD10, COMM domain containing 10 AAD44489 PSFEp758H0811 yes, none DQ000506 25,466 D, 5
51433 ANAPC5, anaphase promoting complex 
subunit 5
BAA76629 PSFEp758E0214 no 47,174 B, 8
51451 LCMT1, leucine carboxyl methyltransferase 1 AAH01214 PSFEp758H0126 partly, none 41,303 B, 11
51534 C6orf55, chromosome 6 open reading frame 
55
AAF76210 PSFEp758H0426 partly, none 41,303 B, 13
51629 CGI-69, CGI-69 AAD34064 PSFEp758D0316 no 63,564 B, 6
51678 MPP6, membrane protein, palmitoylated 6 CAB66770 PSFEp250E023 yes, none DQ000583 64,044 E, 27
54816 SUHW4, suppressor of hairy wing homolog 4 
(Drosophila)
CAB66569 PSFEp250G074 yes, none DQ000587 27,032 E, 22
55255 WDR41, WD repeat domain 41 CAD38853 PSFEp250E105 yes, none DQ000563 26,313
55276 PGM2, phosphoglucomutase 2 CAB66640 PSFEp250B113 partly, none 71,239 B, 26
56681 SARA1, SAR1a gene homolog 1 (S. cerevisiae) CAB66658 PSFEp250G115 yes, none DQ000570 25,290 B, 17
56911 C21orf7, chromosome 21 open reading frame 
7
CAD28500 PSFEp250B086 yes, none DQ000571 19,032 E, 6
57019 LOC57019, cytokine induced apoptosis 
inhibitor 1
AAC24311 PSFEp758E0424 yes, none DQ000534 36,506 E, 21
58485 TRAPPC1, trafficking protein particle complex 
1
AAD44697 PSFEp250D071 yes, T350C DQ000537 19,754 E, 1
64284 RAB17, RAB17, member RAS oncogene family CAB66580 PSFEp250E095 yes, none DQ000572 26,398 A, 6
79632 C6orf60, chromosome 6 open reading frame 
60
CAB66701 PSFEp250B044 yes, none DQ000568 34,217 B, 20
79666 PLEKHF2, pleckstrin homology domain 
containing, family F member 2
CAD39132 PSFEp250D054 yes, A271G DQ000581 30,721 A, 9
79791 FBXO31, F-box protein 31 CAB66696 PSFEp250F085 yes, none DQ000585 18,588 E, 12
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brane proteins with hydrophobic surface regions.
The E. coli expression clones of the PSF are publicly avail-
able from the RZPD German Resource Center [44]. The
Additional file 1 is an XML list of these clones. It can be
viewed in a web browser (Figure 3). The Additional file
contains, for each clone:
• Gene ID and name,
• Accession number,
• Cloning details,
• Strain and vector,
• Expected sequence,
• Protein expression results,
• Sequence verification.
Solved structures
As a result of the target selection and cloning described in
this paper, ten novel X-ray structures of human proteins
were determined (Table 3). The structure of one protein,
TRAPPC3/BET-3, was determined after protein expression
in S. cerevisae, while the other proteins were produced in
E. coli.
Discussion
We describe here the strategies and experiments of our
structural genomics project on human proteins. In addi-
tion to the expression of full length proteins, the Protein
Structure Factory has also studied protein domains by
NMR spectroscopy, which has been described elsewhere
[45-47]. Our selection of full length target proteins was
mainly determined by the availability of full length cDNA
clones. In addition, biophysical and bioinformatical crite-
ria were applied, leading to a biased selection of target
proteins from the human proteome. Therefore, we expect
that the percentage of proteins that we could express and
purify in soluble form, 18%, is higher than it would be in
a randomly selected set. The low proportion of success-
fully expressed proteins indicates that E. coli is not the
appropriate expression host for many full length human
proteins. High throughput protein expression in alterna-
80347 COASY, Coenzyme A synthase AAF87955 PSFEp250A053 yes, none DQ000551 33,147 C, 29
80895 ILKAP, integrin-linked kinase-associated 
serine/threonine phosphatase 2C
CAB66784 PSFEp250D083 yes, none DQ000569 45,832 B, 19
81876 RAB1B, RAB1B, member RAS oncogene family CAB66570 PSFEp250C128 no 25,094 A, 12
81889 DKFZP566J2046, fumarylacetoacetate 
hydrolase domain containing 1
CAB66654 PSFEp250B074 yes, none DQ000567 27,766 B, 24
83538 DKFZP434H0115, hypothetical protein 
DKFZp434H0115
CAB66694 PSFEp250G093 partly, none 79,584 E, 11
83543 C9orf58, chromosome 9 open reading frame 
58
CAB66501 PSFEp250B085 yes, none DQ000573 19,990 B, 25
83667 SESN2, sestrin 2 CAB66486 PSFEp250F043 yes, none DQ000576 57,420 E, 7
84072 NOHMA, HORMA domain containing protein CAB66689 PSFEp250F083 yes, none DQ000561 47,343 E, 4
84324 CIP29, cytokine induced protein 29 kDa CAC37950 PSFEp758H1026 yes, none DQ000512 26,594 A, 2
84457 PHYHIPL, phytanoyl-CoA hydroxylase 
interacting protein-like
CAD39006 PSFEp250A084 yes, none DQ000579 45,425 E, 10
84557 MAP1LC3A, microtubule-associated protein 1 
light chain 3 alpha
CAD38714 PSFEp250E106 yes, none DQ000584 17,194 E, 26
91603 MGC20398, hypothetical protein MGC20398 BAB70992 PSFEp758H0526 yes, none DQ000511 44,915 B, 10
94240 EPSTI1, epithelial stromal interaction 1 
(breast)
CAD38599 PSFEp250C015 yes, none DQ000580 25,527 A, 11
112611 RWDD2, RWD domain containing 2 CAB52345 PSFEp758A1024 partly, T709C 35,159 B, 5
118812 C10orf83, chromosome 10 open reading 
frame 83
CAD38849 PSFEp250H085 yes, none DQ000574 19,158 B, 23
122060 FLJ30046, hypothetical protein FLJ30046 CAD38891 PSFEp250E015 yes, none DQ000577 23,468 E, 8
136319 MTPN, myotrophin CAD38909 PSFEp250D016 yes, none DQ000582 15,817 A, 7
140856 C20orf79, chromosome 20 open reading 
frame 79
CAB56175 PSFEp758G0224 yes, G258T DQ000527 20,585 A, 19
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[48] has been established and will lead to better success
rates in future projects.
Generally, clones that did express a soluble protein were
verified by DNA sequencing, while clones that did not
express or expressed an insoluble product were usually
not sequence verified. It cannot be ruled out that some of
the unsuccessful clones contain sequence errors intro-
duced during cloning. Since template cDNA clones of the
IMAGE consortium with only partial sequence informa-
tion were used for most cloning experiments, expression
clones that were not sequence verified might represent
splice variants or isoforms of the original target. The dis-
tribution of mean net charge and length was similar
among successfully expressed and all proteins, while very
hydrophobic proteins were generally not expressed well in
our E. coli expression system.
Future efforts in structural genomics of mammalian pro-
teins will benefit from a much better supply of full length
cDNA clones. Clones prepared for protein expression by
resource centres and commercial suppliers are becoming
available now. With such resources, alternative target
selection strategies will become feasible that will not be
restricted by the availability of cDNA clones. Instead, all
potential target proteins, including splice variants, could
be clustered by similarity and the most suitable members
of each cluster could be selected by appropriate criteria as
outlined in the Background section.
In our approach, we have excluded certain types of pro-
teins such as membrane proteins and very large proteins.
A structural genomics approach that includes membrane
proteins would require standard protocols to optimise
expression conditions and detergents [49]. The best strat-
egy to study large proteins is to divide them into domains
and smaller regions. However, such smaller constructs
usually have to be designed manually.
All clones listed in the supplementary file (Additional file
1) and Table 2 are available to the research community.
Thereby we hope to facilitate further functional character-
isation of this set of human proteins.
Materials and Methods
Cloning with restriction enzymes
cDNA inserts were amplified by PCR primers carrying tails
with BamHI and NotI sites and cloned into the respective
sites of one of the expression vectors pQTEV, pQStrep2 or
pGEX-6p1. This had the drawback that the restriction sites
chosen for cloning might occur in the insert. In such cases,
compatible overhangs were produced by alternative
enzymes or by the hetero-stagger cloning method [50].
Alternative enzymes are BglII for BamHI and the type IIs
enzymes BpiI, Eco31I, Esp3I, which can replace both
BamHI and NotI. Type IIs enzymes cut outside their recog-
nition sequence and can produce arbitrary overhangs.
PCR Primer design
PCR primers with tails carrying restriction enzyme cleav-
age sites were designed automatically by a Perl program.
The primer design program adjusts the length of the prim-
ers to achieve a melting temperature close to a common
default. Then, restriction enzymes that do not cut within
the respective cDNA sequence are selected by the program
and restriction enzyme sites are attached to the primer
sequences. Finally, since restriction enzymes do not cut
well at the very end of a DNA molecule, an additional
short nucleotide tail is automatically attached to the prim-
ers. The sequence of this tail is optimised to minimise for-
mation of secondary structure, hairpins or dimerisation. A
Java version of the primer design software, 'ORFprimer', is
publicly available [51].
Automated high-throughput cloning, protein expression 
and purification
PCR primers and cDNA clones were delivered in 96-well
microplate format. Upon delivery, plates with PCR prim-
ers and template clones were reformatted to obtain corre-
The supplementary XML Additional file 1 file displayed in a web browserFigure 3
The supplementary XML Additional file 1 file displayed in a 
web browser.Page 10 of 13
(page number not for citation purposes)
Microbial Cell Factories 2005, 4:21 http://www.microbialcellfactories.com/content/4/1/21sponding plate positions by a Zinsser Speedy pipetting
robot. The PCR master mix (Roche Expand) and cDNA
primers (10 µM stocks) were pipetted into a PCR micro-
plate with a multichannel pipet. Template clone bacteria
were added with a 96-pin steel replicating device from
overnight cultures in microtitre plates. PCR product size
and yield was determined by agarose gel electrophoresis
and the software Phoretix 1D Quantifier (Nonlinear
dynamics). PCR products were purified with magnetic
beads on the pipetting robot with a system that has been
developed at the Max Planck Institute of Molecular Genet-
ics in collaboration with Bruker Daltonics (Bruker genop-
ure kit). The correct restriction enzyme master mixes were
automatically added and the digested fragments were
purified again, analysed by agarose gel electrophoresis
and quantified. The robot then adjusted DNA
concentrations to a common default by dilution. Liga-
tions were set up manually with a multichannel pipet, and
SCS1 E. coli cells carrying pRARE were transformed in a
PCR microplate by chemical transformation on a PCR
machine [52]. Transformed cells were manually plated on
individual agar plates. Four clones were picked per trans-
formation and were checked by PCR using vector primers.
E. coli expression clones were ready for protein expression
at this stage.
Primer sequences and template clones for cloning of the
target cDNAs are listed in the supplementary XML file,
Additional file 1.
The characterisation of expression clones by parallel
expression and protein purification is described in refer-
ence [43].
Sequence analysis
Sequence analysis software was run with default settings
unless indicated otherwise. The mean charge of a protein
was calculated as the difference of the number of positive
and negatively charged amino acids (Lys, Arg and Glu,
Asp, respectively) divided by the protein length. The mean
hydrophobicity was calculated with the Kyte and Doolit-
tle hydropathy index [53], obtained from the EMBOSS
package [54]. The index values were added up for a given
protein and divided by the protein length.
Authors' contributions
• Study design and coordination: KB, HL, UHe
• Bioinformatics: UHa, BS, JS, PB, VS, KB
• E. coli cloning: VS, KB
• E. coli protein work: CS, KB
• Manuscript, figures, XML file preparation: KB
Additional material
Acknowledgements
We wish to thank Ulf Lenski for help with sequence analysis and Janett 
Tischer for technical assistance. This work was funded by the German Fed-
eral Ministry of Education and Research (BMBF) through the Leitprojek-
tverbund Proteinstrukturfabrik and the National Genome Network NGFN 
Table 3: Novel human protein structures The structures of full length proteins solved by the Protein Structure Factory.
NCBI Entrez 
gene ID
Name GenBank protein 
accession
PDB ID Reference
5716 Gankyrin AAH11960 1QYM [55]
10290 APEG1, aortic preferentially expressed protein 1 AAH06346 1U2H
81889 Fumarylacetoacetate hydrolase family member FLJ36880 CAB66654 1SAW [56]
28970 PTD012 CAB66540 1XCR
10247 14.5 kDa translational inhibitor protein, p14.5 CAA64670 1ONI [57]
27095 BET3, trafficking protein particle subunit AAB96936 1SZ7 [58]
5184 Peptidase D AAH28295
51076 CutC copper transporter homolog, CGI-32 AAH21105
122553 TPC6 CAI46185 2BJN [59]
6449 Nicotinamide mononucleotide adenylyltransferase NP_003012 1GZU [60]
Additional File 1
A ZIP archive that contains the XML list psfClones.xml of PSF clones 
available at the RZPD and the XSL stylesheet psfToHtml.xsl to display the 
XML file in a web browser. The two files should be extracted from the ZIP 
archive into a local directory. Then psfClones.xml can be opened with a 
current web browser like Mozilla or Internet Explorer. 1414 Clones for 
537 target proteins are described in the XML file. It lists the gene, cloning 
details, expected sequence, protein expression results and the degree of 
sequence verification for each clone.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
2859-4-21-S1.zip]Page 11 of 13
(page number not for citation purposes)
Microbial Cell Factories 2005, 4:21 http://www.microbialcellfactories.com/content/4/1/21(FKZ 01GR0471, 01GR0472) and with support by the Fonds der Che-
mischen Industrie to U.H. Support by the Berlin Senate and the European 
Fund for Regional Development (EFRE) is also gratefully acknowledged.
References
1. Heinemann U, Büssow K, Mueller U, Umbach P: Facilities and
methods for the high-throughput crystal structure analysis
of human proteins.  Accounts of Chemical Research 2003,
36(3):157-163.
2. Protein Structure Factory   [http://www.proteinstrukturfab
rik.de]
3. Zhang C, Kim SH: Overview of structural genomics: from
structure to function.  Current Opinion in Chemical Biology 2003,
7(1):28-32.
4. Todd AE, Marsden RL, Thornton JM, Orengo CA: Progress of
structural genomics initiatives: an analysis of solved target
structures.  Journal of Molecular Biology 2005, 348(5):1235-1260.
5. Gilbert M, Albala Joanna S: Accelerating code to function: Sizing
up the protein production line.  Current Opinion in Chemical Biology
2002, 6(1):102-105.
6. Yokoyama S: Protein expression systems for structural
genomics and proteomics.  Current Opinion in Chemical Biology
2003, 7(1):39-43.
7. Kigawa T, Yabuki T, Yoshida Y, Tsutsui M, Ito Y, Shibata T, Yokoyama
S: Cell-free production and stable-isotope labeling of milli-
gram quantities of proteins.  FEBS Letters 1999, 442(1):15-19.
8. Tyler RC, Aceti DJ, Bingman CA, Cornilescu CC, Fox BG, Frederick
RO, Jeon WB, Lee MS, Newman CS, Peterson FC, Phillips GNJ, Sha-
han MN, Singh S, Song J, Sreenath HK, Tyler EM, Ulrich EL, Vinarov
DA, Vojtik FC, Volkman BF, Wrobel RL, Zhao Q, Markley JL: Com-
parison of cell-based and cell-free protocols for producing
target proteins from the Arabidopsis thaliana genome for
structural studies.  Proteins 2005, 59:633-643.
9. Holz C, Hesse O, Bolotina N, Stahl U, Lang C: A micro-scale proc-
ess for high-throughput expression of cDNAs in the yeast
Saccharomyces cerevisiae.  Protein Expression & Purification 2002,
25(3):372-378.
10. Boettner M, Prinz B, Holz C, Stahl U, Lang C: High-throughput
screening for expression of heterologous proteins in the
yeast Pichia pastoris.  Journal of Biotechnology 2002, 99(1):51-62.
11. Holz C, Prinz B, Bolotina N, Sievert V, Büssow K, Simon B, Stahl U,
Lang C: Establishing the yeast Saccharomyces cerevisiae as a
system for expression of human proteins on a proteome-
scale.  Journal of Structural and Functional Genomics 2003, 4(2/
3):97-108.
12. Studier FW, Rosenberg AH, Dunn JJ, Dubendorff JW: Use of T7
RNA polymerase to direct expression of cloned genes.  Meth-
ods in Enzymology 1990, 185:60-89.
13. Hochuli E, Dobeli H, Schacher A: New metal chelate adsorbent
selective for proteins and peptides containing neighboring
histidine residues.  Journal of Chromatography 1987, 411:177-184.
14. Schmidt TG, Skerra A: The random peptide library-assisted
engineering of a C-terminal affinity peptide, useful for the
detection and purification of a functional Ig Fv fragment.  Pro-
tein Engineering 1993, 6(1):109-122.
15. Schmidt TGM, Koepke J, Frank R, Skerra A: Molecular interaction
between the Strep-tag affinity peptide and its cognate tar-
get, streptavidin.  Journal of Molecular Biology 1996,
255(5):753-766.
16. Mueller U, Büssow K, Diehl A, Bartl FJ, Niesen FH, Nyarsik L, Heine-
mann U: Rapid purification and crystal structure analysis of a
small protein carrying two terminal affinity tags.  Journal of
Structural and Functional Genomics 2004, 4:217-225.
17. Kane JF: Effects of rare codon clusters on high-level expres-
sion of heterologous proteins in Escherichia coli.  Current Opin-
ion in Biotechnology 1995, 6(5):494-500.
18. Brinkmann U, Mattes RE, Buckel P: High-level expression of
recombinant genes in Escherichia coli is dependent on the
availability of the DNAY gene product.  Gene 1989,
85(1):109-114.
19. Novy R, Drott D, Yaeger K, Mierendorf R: Overcoming the codon
bias of E.coli for enhanced protein expression.  inNovations
2001, 12:1-3.
20. Krogh A, Larsson B, von Heijne G, Sonnhammer ELL: Predicting
transmembrane protein topology with a hidden Markov
model: Application to complete genomes.  Journal of Molecular
Biology 2001, 305(3):567-580.
21. TMHMM   [http://www.cbs.dtu.dk/services/TMHMM/]
22. Dyson HJ, Wright PE: Coupling of folding and binding for
unstructured proteins.  Current Opinion in Structural Biology 2002,
12(1):54-60.
23. Wootton JC, Federhen S: Analysis of compositionally biased
regions in sequence databases.  Methods in Enzymology 1996,
266:554-571.
24. Wootton JC, Federhen S: Statistics of local complexity in amino
acid sequences and sequence databases.  Computers & Chemistry
1993, 17:149-163.
25. Wootton JC: Non-globular domains in protein sequences:
automated segmentation using complexity measures.  Com-
puters & Chemistry 1994, 18(3):269-285.
26. COILS   [http://www.russell.embl.de/cgi-bin/coils-svr.pl]
27. Lupas A, Van Dyke M, Stock J: Predicting coiled coils from pro-
tein sequences.  Science 1991, 252(5010):1162-1164.
28. Lupas A: Prediction and analysis of coiled-coil structures.
Methods in Enzymology 1996, 266:513-525.
29. Eisenhaber F, Bork P: Wanted: Subcellular localization of pro-
teins based on sequence.  Trends in Cell Biology 1998, 8(4):169-170.
30. Meta_Annotator   [http://mendel.imp.univie.ac.at/aat/
CellLoc_MetaA]
31. Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt
K, Feng Z, Gilliland GL, Iype L, Jain S, Fagan P, Marvin J, Padilla D, Rav-
ichandran V, Schneider B, Thanki N, Weissig H, Westbrook JD, Zard-
ecki C: The protein data bank.  Acta Crystallographica Section D
2002, 58(Pt 6 Pt 1):899-907.
32. Altschul SF, Madden TL, Schaeffer AA, Zhang J, Zhang Z, Miller W,
Lipman DJ: Gapped BLAST and PSI-BLAST: A new genera-
tion of protein database search programs.  Nucleic Acids
Research 1997, 25(17):3389-3402.
33. Lennon G, Auffray C, Polymeropoulos M, Soares MB: The
I.M.A.G.E. consortium: an integrated molecular analysis of
genomes and their expression.  Genomics 1996, 33:151-152.
34. dbEST   [http://www.ncbi.nlm.nih.gov/dbEST]
35. Bannasch D, Mehrle A, Glatting KH, Pepperkok R, Poustka A, Wie-
mann S: LIFEdb: a database for functional genomics experi-
ments integrating information from external sources, and
serving as a sample tracking system.  Nucleic Acids Research
2004, 32(Special Issue SI):D505-D508.
36. Wiemann S, Weil B, Wellenreuther R, Gassenhuber J, Glassl S,
Ansorge W, Bocher M, Blocker H, Bauersachs S, Blum H, Lauber J,
Dusterhoft A, Beyer A, Kohrer K, Strack N, Mewes HW, Ottenwal-
der B, Obermaier B, Tampe J, Heubner D, Wambutt R, Korn B, Klein
M, Poustka A: Toward a catalog of human genes and proteins:
sequencing and analysis of 500 novel complete protein cod-
ing human cDNAs.  Genome Research 2001, 11(3):422-435.
37. Büssow K, Nordhoff E, Lübbert C, Lehrach H, Walter G: A human
cDNA library for high-throughput protein expression
screening.  Genomics 2000, 65(1):1-8.
38. Büssow K, Cahill D, Nietfeld W, Bancroft D, Scherzinger E, Lehrach
H, Walter G: A method for global protein expression and anti-
body screening on high-density filters of an arrayed cDNA
library.  Nucleic Acids Research 1998, 26(21):5007-5008.
39. Büssow K, Quedenau C, Sievert V, Tischer J, Scheich C, Seitz H,
Hieke B, Niesen FH, Götz F, Harttig U, Lehrach H: A catalogue of
human cDNA expression clones and its application to struc-
tural genomics.  Genome Biology 2004, 5:R71.
40. The hEx1 Database   [http://www.proteinstrukturfabrik.de/hex1]
41. Hubbard T, Barker D, Birney E, Cameron G, Chen Y, Clark L, Cox T,
Cuff J, Curwen V, Down T, Durbin R, Eyras E, Gilbert J, Hammond M,
Huminiecki L, Kasprzyk A, Lehvaslaiho H, Lijnzaad P, Melsopp C,
Mongin E, Pettett R, Pocock M, Potter S, Rust A, Schmidt E, Searle S,
Slater G, Smith J, Spooner W, Stabenau A, Stalker J, Stupka E, Ureta-
Vidal A, Vastrik I, Clamp M: The Ensembl genome database
project.  Nucleic Acids Research 2002, 30(1):38-41.
42. Aslanidis C, de Jong PJ: Ligation-independent cloning of PCR
products (LIC-PCR).  Nucleic Acids Research 1990,
18(20):6069-6074.
43. Scheich C, Sievert V, Büssow K: An automated method for high-
throughput protein purification applied to a comparison of
His-tag and GST-tag affinity chromatography.  BMC
Biotechnology 2003, 3:12.
44. German Resource Centre (RZPD)   [http://www.rzpd.de]Page 12 of 13
(page number not for citation purposes)
Microbial Cell Factories 2005, 4:21 http://www.microbialcellfactories.com/content/4/1/21Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
45. Scheich C, Leitner D, Sievert V, Leidert M, Schlegel B, Simon B, Letu-
nic I, Büssow K, Diehl A: Fast identification of folded human
protein domains expressed in E. coli suitable for structural
analysis.  BMC Structural Biology 2004, 4:4.
46. Brockmann C, Leitner D, Labudde D, Diehl A, Sievert V, Büssow K,
Kühne R, Oschkinat H: The solution structure of the SODD
BAG domain reveals additional electrostatic interactions in
the HSP70 complexes of SODD subfamily BAG domains.
FEBS Letters 2004, 558(1-3):101-106.
47. Soukenik M, Diehl A, Leidert M, Sievert V, Büssow K, Leitner D,
Labudde D, Ball LJ, Lechner A, Nagler DK, Oschkinat H: The SEP
domain of p47 acts as a reversible competitive inhibitor of
cathepsin L.  FEBS Letters 2004, 576(3):358-362.
48. McCall EJ, Danielsson A, Hardern IM, Dartsch C, Hicks R, Wahlberg
JM, Abbott WM: Improvements to the throughput of recom-
binant protein expression in the baculovirus/insect cell
system.  Protein Expr Purif 2005, 42(1):29-36.
49. Eshaghi S, Hedren M, Nasser MI, Hammarberg T, Thornell A, Nord-
lund P: An efficient strategy for high-throughput expression
screening of recombinant integral membrane proteins.  Pro-
tein Sci 2005, 14(3):676-683.
50. Li C, Evans RM: Ligation independent cloning irrespective of
restriction site compatibility.  Nucleic Acids Research 1997,
25(20):4165-4166.
51. ORFprimer   [http://www.proteinstrukturfabrik.de/ORFprimer]
52. Inoue H, Nojima H, Okayama H: High efficiency transformation
of Escherichia coli with plasmids.  Gene 1990, 96(1):23-28.
53. Kyte J, Doolittle RF: A simple method for displaying the hydro-
pathic character of a protein.  Journal of Molecular Biology 1982,
157(1):105-132.
54. Rice P, Longden I, Bleasby A: EMBOSS: the European Molecular
Biology Open Software Suite.  Trends in Genetics 2000,
16(6):276-277.
55. Manjasetty BA, Quedenau C, Sievert V, Büssow K, Niesen F, Del-
brück H, Heinemann U: X-ray structure of human gankyrin, the
product of a gene linked to hepatocellular carcinome.  Pro-
teins: Structure, Function and Genetics 2004, 55(1):214-217.
56. Manjasetty BA, Niesen FH, Delbruck H, Gotz F, Sievert V, Bussow K,
Behlke J, Heinemann U: X-ray structure of fumarylacetoacetate
hydrolase family member homo sapiens FLJ36880.  Biological
Chemistry 2004, 385(10):935-942.
57. Manjasetty BA, Delbrück H, Pham DT, Mueller U, Fieber-Erdmann M,
Scheich C, Sievert V, Büssow K, Niesen F, Weihofen W, Loll B,
Saenger W, Heinemann U: Crystal structure of Homo sapiens
protein hp14.5.  Proteins: Structure, Function and Bioinformatics 2004,
54:797-800.
58. Turnbull AP, Kümmel D, Prinz B, Holz C, Schultchen J, Lang C, Niesen
FH, Hofmann KP, Delbrück H, Behlke J, Müller EC, Jarosch E, Sommer
T, Heinemann U: Structure of palmitoylated BET3: insights
into TRAPP complex assembly and membrane localization.
EMBO Journal 2005, 24(5):875-884.
59. Kümmel D, Müller JJ, Roske Y, Misselwitz R, Büssow K, Heinemann
U: Structure of the TRAPP subunit TPC6 suggests a model
for a TRAPP subcomplex.  EMBO Reports 2005, 6(8):787-793.
60. Werner E, Ziegler M, Lerner F, Schweiger M, Heinemann U: Crystal
structure of human nicotinamide mononucleotide adenylyl-
transferase in complex with NMN.  FEBS Letters 2002, 516(1-
3):239-244.Page 13 of 13
(page number not for citation purposes)
